Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

NCT03045393 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Inadequate enrollment

Conditions

Breast Cancer Triple Negative

Interventions

DRUG: Mirvetuximab Soravtansine (IMGN853)

Sponsor

Duke University

Collaborators

[object Object]